The Effects of Use of Long-Term Second-Generation Antipsychotics on Liver and Kidney Function: A Prospective Study

Evangelia Papatriantafyllou 1, Dimitris Efthymiou 2, Maria Markopoulou 3, Efthymia-Maria Sakellariou 4 and Emilia Vassilopoulou 1,*  

1 Department of Nutritional Sciences and Dietetics, International Hellenic University, 57400 Thessaloniki, Greece; e.papatriantafyllou@hotmail.com  
2 Department of Psychiatry, Division of Neurosciences, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; dimitrisefthy@gmail.com  
3 Department of Forensic Psychiatry, Psychiatric Hospital of Thessaloniki, 56429 Thessaloniki, Greece; marmark33@yahoo.gr  
4 Psychiatric Clinic, General University Hospital, 41110 Larissa, Greece; efthymiamaria@yahoo.com  
* Correspondence: vassilopoulouemilia@gmail.com  

Abstract: (1) Background: The second-generation antipsychotics (SGAPs) induce metabolic and inflammatory side effects, but documentation of their effects on the liver and kidneys is scarce. Aim: To study the three-year fluctuation of selected markers of renal and hepatic function in forensic psychiatric patients receiving SGAPs for more than five years. (2) Methods: Thirty-five forensic psychiatric patients (N = 35) were classified into two groups according to the type of SGAPs used for their treatment and the relevant risk of weight gain and metabolic complications. The three-year medication history, anthropometric data and biochemical data relevant to renal and hepatic function were retrieved from the individual medical files, specifically: serum levels of urea, uric acid, creatinine, alkaline phosphatase and amylase; the liver function enzymes, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and γ-glutamyl transpeptidase (γ-GT), and also the inflammatory index C-reactive protein (CRP). (3) Results: The patients receiving the SGAPs with a low risk for weight gain showed no significant fluctuation in the biochemical markers over the three-year period. The patients receiving the SGAPs with a high risk for weight gain showed significant differences between at least two measurements of uric acid (p = 0.015), SGOT (p = 0.018) and SGPT (p = 0.051). They showed significantly higher levels of creatinine in the third year compared to the second year (p = 0.029), and SGOT in the second year compared to the first (p = 0.038), and lower levels of SGPT in the third year compared to the second (p = 0.024). (4) Conclusion: In addition to consideration of possible metabolic and inflammatory complications, the choice of an antipsychotic drug for long-term treatment should also take into account the risk of hepatotoxicity and kidney damage.  

Keywords: forensic psychiatry; antipsychotic drugs; liver; kidney  

1. Introduction

In forensic psychiatry, mentally disordered offenders are treated in a forensic psychiatric hospital, and their treatment often includes the administration of antipsychotic drugs (APs) [1]. APs are used to treat schizophrenia, bipolar disorder, monopolar depression, and are also commonly used in a number of other psychiatric disorders [2]. AP treatment for psychiatric disorders, as in forensic psychiatric patients, is often a long-term or even lifelong procedure. These patients are at high risk of AP-related adverse side effects, from both long-term and episodic treatment [3].

Various studies have shown that the most common serious disturbances caused by APs are weight gain (WG) [4,5], metabolic syndrome [6], diabetes mellitus (DM), cardiovascular disease (CVD) [7], acute kidney injury (AKI) [8,9] and chronic kidney disease (CKD) [10,11].
and liver damage [12]. AKI survivors frequently develop CKD [13] and CVD is the main cause of mortality among CKD patients, both in adults and in children [14]. Recently, several studies for early detection of AKI and CKD have been reported in order to prevent progression of kidney disease and CVD events [15–18].

Severe metabolic complications in forensic psychiatric patients may be relevant to the multipharmacotherapy used for their treatment, in comparison to monotherapy, that is generally relevant to milder complications [19]. Medication can seriously affect liver function [20], as the liver is the major site of metabolism of drugs, including antidepressants (ADs) and APs [21]. More than 160 psychotropic drugs have been shown to produce hepatic side effects [22], and a recent study reported that psychotropic drugs were responsible for 7.6% of cases of drug-induced liver injury (DILI) in a group of 185 patients [23]. It is of note that both first-generation APs (FGAPs) and second-generation APs (SGAPs) are associated with a risk of hepatotoxicity [24].

Fluoxetine, paroxetine, sertraline, citalopram, and fluvoxamine are selective serotonin reuptake inhibitors (SSRIs) that have been associated with hepatotoxicity. The serotonin and norepinephrine reuptake inhibitors (SNRIs), venlafaxine, duloxetine, and trazodone, have also been strongly associated with hepatotoxic side effects [24]. Over-the-counter FGAPs, such as chlorpromazine and haloperidol, often cause serum elevation of the liver enzymes and severe liver damage. Of the SGAPs, clozapine is associated with hepatotoxicity [25]. An asymptomatic increase in serum transaminase levels is observed in up to 60% of patients treated with clozapine, with 15–30% showing a double or triple increase [26].

Moreover, observational studies have linked SGAPs to an increased risk of both AKI and CKD [8–12]. Reports have described an association of clozapine, olanzapine, and quetiapine with interstitial nephritis and AKI [27,28]. According to the study of Højlund and colleagues [12], all SGAPs, with the exception of aripiprazole, were associated with an increased risk of CKD. The risk was most pronounced for clozapine (aOR 1.81, 95% CI: 1.22 to 2.69) followed by olanzapine (aOR 1.41, 95% CI: 1.19 to 1.65) and quetiapine (aOR 1.28, 95% CI: 1.17 to 1.42) [12].

The aim of this study was to investigate the three-year fluctuation of selected markers of renal and hepatic function in forensic psychiatric patients receiving SGAP medication for more than five years, in relation to body weight, the serum level of C-reactive protein (CRP), and the type of AP.

2. Materials and Methods
2.1. Patients

This prospective, three-year study included patients with psychotic disorders, all of whom were offenders, classified as not responsible for their criminal actions, and hospitalized in the Thessaloniki Psychiatric Hospital following a relevant judicial decision. The International Statistical Classification of Diseases (ICD-10) was used for the diagnosis of the mental disorders by qualified psychiatrists at the hospital.

At the start of the study (T1), 49 patients were screened for eligibility to inclusion. Inclusion criteria included more than five years of SGAP use. After screening, 35 patients were eligible for participation, as 13 were receiving SGAPs for less than five years, while one had an incomplete medical record at T1. All patients were informed about the scope of the study and informed consent was obtained. The study was approved by the Scientific Committee of the hospital (code number: Δ3Β/34800/21/07/2020) and the Research Ethics Committee of the Aristotle University of Thessaloniki (code number 4/26.01.2021), and complied with the International Code of Medical Ethics of the World Medical Association and the Helsinki Declaration. For the purposes of the study, patients were classified into two groups, based on the type of SGAP, as previously described in detail [1]: AP1, relevant to low to moderate risk of WG from the baseline weight and less risk of metabolic complications, namely aripiprazole, amisulpride, quetiapine, risperidone, and ziprasidone, and AP2, linked with a higher risk of WG from the baseline weight and a higher risk of metabolic complications, namely paliperidone, olanzapine, asenapine, and clozapine.
Clinical information was collected from the hospital records of the patients, including the SGAPs used, changes in prescribed SGAPs over time, and medications used for the treatment of other chronic diseases, such as lipidemia, CVD, and type II DM. A flow chart of the study design is presented in Figure 1.

Figure 1. Flow chart of the prospective study.

SGAPs: second-generation antipsychotics. AP1: second-generation antipsychotics linked with a higher risk of weight gain (AP1). AP2: second-generation antipsychotics linked with a higher risk of weight gain (AP2). SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic pyruvic transaminase; γ-GT: gamma-glutamyl transpeptidase; CRP: C-reactive protein.

2.2. Biochemical/Hematological Assessment

Venous blood samples were obtained from all the participants, after overnight fasting, during the first quarter of the years in the three-year study period (i.e., T1: 2018, T2: 2019, T3: 2020), as part of their routine monitoring procedure. Serum and plasma aliquots were isolated and stored at −80 °C until further analysis.

The specific markers measured were the serum levels of urea, uric acid, creatinine, alkaline phosphatase and amylase, and the liver function enzymes, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), and gamma-glutamyl transpeptidase (γ-GT). Measurements were performed with an automatic analyzer (Toshiba TBA 120FR; Toshiba MedicalSystems Co., Ltd., Tokyo, Japan) under standard conditions, on the hospital premises.

2.3. Anthropometric Measurements

On the morning of blood collection, all participants underwent anthropometric measurements, after fasting for at least 8 h, by one trained investigator. A commercial stadiometer (Leicester Height Measure, Invicta Plastics Ltd., Oadby, UK) was used to measure height to the nearest 0.1 cm; height was measured with the participants barefoot, their shoulders in a relaxed position, their arms hanging freely, and their heads in the Frankfort horizontal plane. Weight was measured with the participants barefoot and in light clothing to the nearest 0.1 kg using a TANITA RD-545 (“RD-545-Connected smart scale | Tanita Official Store”, n.d.). Body mass index (BMI) was calculated from the current weight and height, as weight (kg) by height squared (m²). The waist circumference (WC) was measured with a SECA flexible, inextensible measuring tape, with an accuracy of 1 mm, on a horizontal
plane, after exhalation, at a point equidistant from the lowest floating rib and the upper border of the iliac crest.

2.4. Statistical Analysis

The statistical analysis was performed with the SPSS23 package. The categorical values were expressed as mean ± standard deviation (SD), while the non-categorical values as median (interquartile range (IQR)). The possible differences between biochemical characteristics at two time periods for 2dependent samples was determined with the t-test or with the Wilcoxon test, depending on the regularity of the values. Significant differences between the groups of patients, AP1 and AP2, based on the SGAP drug they were receiving, were explored by repeated measures ANOVA. When the differences in observations violated the hypothesis of regularity, the difference tests were performed with the Friedman method.

Multiple regression analysis was performed to explore the effect of weight, BMI, and CRP on changes in the renal and hepatic biochemical markers.

3. Results

Of the 49 forensic psychiatric patients initially assessed in the study, 35 fulfilled the criteria for inclusion; among the excluded, 13 received SGAPs for less than 5 years, while 31 (91%) were males, and 17 were receiving AP1 and 18 AP2 medication. Their demographic and clinical characteristics are presented in Table 1. The two groups had a similar age range (AP1: 52.35 ± 12.68 years; AP2: 48.56 ± 12.65 years, \(p = 0.38\)). All patients received the same SGAP over the study period (i.e., no in-person changes in SGAP received). The patients receiving AP2 medication more frequently used anti-diabetic and anti-lipidemic medication, and medication for CVD (i.e., heart rate lowering agents, such as ivabradine, beta blockers, such as propranolol, and calcium channel blockers, such as amlodipine), than the patients receiving AP1.

### Table 1. Demographic and clinical characteristics of the forensic psychiatric patients at the start of the study (T1) (N = 35), according to the type of antipsychotic (AP) medication.

|          | AP1 | AP2 |
|----------|-----|-----|
| N        | 17  | 18  |
| Males    | 16 (94%) | 15 (83.33%) |
| Antipsychotics | 17 | 18 |
| Anticoagulants | 5  | 1   |
| Antihypertensives | 3  | 4   |
| Antidiabetic | 2  | 3   |
| Antilipidemic | 2  | 5   |
| Medication for CVD | 7  | 7   |

AP1: Antipsychotic medication associated with low risk of weight gain; AP2: Antipsychotic medication associated with higher risk of weight gain; CVD: cardiovascular disease.

The AP1 group presented no changes over the study period in the biochemical markers measured (Table 2).

Patients in the AP2 group presented a significant difference in serum level of uric acid \(p = 0.01\), SGOT \(p = 0.02\), and SGPT \(p = 0.05\) in at least one measurement over the study period (Table 3). Specifically, AP2 patients showed significantly higher mean uric acid level in the T3 than in the T2 measurement \(p = 0.01\), and significantly higher creatinine level in the T3 than in the T1 measurement \(p = 0.03\). SGOT levels in the AP2 patients were significantly higher in T2 than in the T1 measurement \(p = 0.04\), and SGPT levels were significantly lower in the T3 than in the T2 measurement \(p = 0.02\).
Table 2. Changes (difference tests) in the biochemical measurements of forensic psychiatric patients taking second-generation antipsychotics with a low risk of weight gain (AP1) over the three-year study period (time points T1, T2, T3) (N = 17).

| Biochemical Measurement | T1       | T2       | T3       | T1-T2 p-Value | T2-T3 p-Value | T1-T3 p-Value | Overall Difference during the 3-Year Period p-Value |
|-------------------------|----------|----------|----------|---------------|---------------|---------------|--------------------------------------------------|
| Urea (mg/dL)            | 27.12    | 27.35    | 27.29    | 0.89          | 0.97 **       | 0.94 **       | 0.79                                             |
|                         | (11.77)  | (9.58)   | (8.34)   |               |               |               |                                                   |
| Uric acid (mg/dL)       | 4.19     | 4.20     | 4.30     | 0.067 **      | 0.97          | 0.12 **       | 0.06                                             |
|                         | (1.52)   | (1.35)   | (1.70)   |               |               |               |                                                   |
| Serum creatinine (mg/dL)| 0.83     | 0.81     | 0.80     | 0.88 **       | 0.28 **       | 0.400 **      | 0.53 ***                                          |
|                         | (0.24)   | (0.15)   | (0.24)   |               |               |               |                                                   |
| SGOT (U/L)              | 17.00    | 18.00    | 17.00    | 0.79 **       | 0.48          | 0.85 **       | 0.34                                             |
|                         | (7.00)   | (9.00)   | (10.00)  |               |               |               |                                                   |
| SGPT (U/L)              | 20.00    | 21.00    | 20.00    | 0.22          | 0.26          | 0.14 **       | 0.39                                             |
|                         | (11.00)  | (17.00)  | (19.00)  |               |               |               |                                                   |
| γ-GT (U/L)              | 26.00    | 24.00    | 21.00    | 0.63 **       | 0.12          | 0.56 **       | 0.48                                             |
|                         | (13.00)  | (18.00)  | (19.00)  |               |               |               |                                                   |
| Alkaline phosphatase (U/L) | 79.47    | 80.41    | 79.29    | 0.93 **       | 0.71 **       | 0.81 **       | 0.86 ***                                          |
|                         | (31.35)  | (36.93)  | (31.47)  |               |               |               |                                                   |
| Amylase (U/L)           | 58.29    | 62.12    | 57.41    | 0.57          | 0.08          | 0.27 **       | 0.19                                             |
|                         | (19.66)  | (14.32)  | (21.30)  |               |               |               |                                                   |

SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic pyruvic transaminase; γ-GT: gamma-glutamyl transpeptidase. All other values are expressed as median (intra-quaternary range, IQR). ** t test was applied for 2 dependent samples; the non-parametric Mann–Whitney test was used for all other samples. *** tests were performed with the parametric test repeated measures ANOVA. All other tests were performed using the non-parametric Friedman test.

Table 3. Changes (difference tests) in the biochemical measurements of forensic psychiatric patients taking second-generation antipsychotics with a higher risk of weight gain (AP2) over the three-year study period (time points T1, T2, T3) (N = 18).

| Biochemical Measurement | T1       | T2       | T3       | T1-T2 p-Value | T2-T3 p-Value | T1-T3 p-Value | Overall Difference during the 3-Year Period p-Value |
|-------------------------|----------|----------|----------|---------------|---------------|---------------|--------------------------------------------------|
| Urea (mg/dL)            | 24.03    | 23.31    | 23.77    | 0.39 **       | 0.81 **       | 0.86 **       | 0.94                                             |
|                         | (8.46)   | (8.52)   | (10.71)  |               |               |               |                                                   |
| Uric acid (mg/dL)       | 4.21     | 4.00     | 4.50     | 0.60          | 0.01 **       | 0.23 **       | 0.01                                             |
|                         | (1.40)   | (2.18)   | (1.55)   |               |               |               |                                                   |
| Serum creatinine (mg/dL)| 0.81     | 0.84     | 0.87     | 0.13          | 0.41 **       | 0.03 **       | 0.16                                             |
|                         | (0.12)   | (0.30)   | (0.31)   |               |               |               |                                                   |
| SGOT (U/L)              | 15.00    | 17.00    | 15.00    | 0.04          | 0.01          | 0.82          | 0.02                                             |
|                         | (4.00)   | (2.00)   | (4.00)   |               |               |               |                                                   |
| SGPT (U/L)              | 17.00    | 18.50    | 14.00    | 0.24 **       | 0.02 **       | 0.06          | 0.05                                             |
|                         | (12.00)  | (16.00)  | (13.00)  |               |               |               |                                                   |
| γ-GT (U/L)              | 24.50    | 24.00    | 24.00    | 0.72          | 0.19          | 0.42 **       | 0.54                                             |
|                         | (18.00)  | (9.00)   | (9.00)   |               |               |               |                                                   |
| Alkaline phosphatase (U/L) | 73.28    | 74.56    | 72.22    | 0.63 **       | 0.33          | 0.41          | 0.09                                             |
|                         | (18.10)  | (22.56)  | (21.89)  |               |               |               |                                                   |
| Amylase (U/L)           | 49.94    | 51.94    | 53.89    | 0.67          | 0.78          | 0.86          | 0.86                                             |
|                         | (21.84)  | (19.33)  | (22.13)  |               |               |               |                                                   |

SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic pyruvic transaminase; γ-GT: gamma-glutamyl transpeptidase. All other values are expressed as median (intra-quaternary range, IQR). ** t test was applied for 2 dependent samples; the non-parametric Mann–Whitney test was used for all other samples. Non-parametric Friedman test was used for all other tests.
Multiple regression analysis was conducted to determine whether the differences in uric acid, creatinine, SGOT, and SGPT in the AP2 participants were affected by weight, BMI, and CRP (Table 4). Due to the small number of individuals in group AP2 (18), all 3 measurements over time for each individual were examined for every determinant.

Table 4. Regression analysis of specific factors for the forensic psychiatric patients taking second-generation antipsychotics with a higher risk of weight gain (AP2).

| Dependent Variable | Independent Variables | B    | S.E. | β     | T    | p   |
|--------------------|-----------------------|------|------|-------|------|-----|
| Uric acid (1)      | Constant              | 3.013| 1.278| 2.358 | 0.02 |
|                    | Weight                | 0.061| 0.024| 0.546 | 2.564| 0.01|
|                    | BMI                   | −0.134| 0.067| −0.432| −2.012| 0.05|
|                    | CRP                   | −0.048| 0.051| −0.124| −0.932| 0.36|
| Serum creatinine (2)| Constant              | 0.482| 0.174| 2.761 | 0.01 |
|                    | Weight                | 0.001| 0.003| 0.066 | 0.303| 0.76|
|                    | BMI                   | 0.012| 0.009| 0.280 | 1.281| 0.21|
|                    | CRP                   | −0.003| 0.007| −0.050| −0.367| 0.71|
| SGOT (3)           | Constant              | 4.205| 7.290| 0.577 | 0.57 |
|                    | Weight                | −0.124| 0.135| −0.190| −0.914| 0.36|
|                    | BMI                   | 0.816| 0.381| 0.450 | 2.141| 0.03|
|                    | CRP                   | 0.496| 0.292| 0.222 | 1.698| 0.09|
| SGPT (4)           | Constant              | −1.128| 8.832| −0.128| 0.89 |
|                    | Weight                | 0.011| 0.164| 0.014 | 0.065| 0.95|
|                    | BMI                   | 0.733| 0.462| 0.342 | 1.587| 0.12|
|                    | CRP                   | −0.366| 0.354| −0.139| −1.033| 0.31|

Table 4. Regression analysis of specific factors for the forensic psychiatric patients taking second-generation antipsychotics with a higher risk of weight gain (AP2).

The first regression model demonstrated the significance for prediction of increase in uric acid level in AT2 patients of weight (t (53) = 2.564, p = 0.01) and BMI (t (53) = −2.012, p = 0.05), explaining 14.1% of its total variability (F (3.50) = 2.741, p = 0.05). Specifically, uric acid level showed a positive correlation with weight (B = 0.061) and a negative correlation with BMI (B = −0.134). Therefore, AP2 patients are expected to have a higher uric acid level as their weight increases while BMI and CRP levels remain stable. In contrast, AP2 patients who have a higher BMI, but constant weight and CRP, are expected to show a decrease in uric acid level.

The third model demonstrated significance in predicting SGOT levels (F(3.50) = 3.599, p = 0.02) explaining 17.8% of the total variability. Specifically, a positive correlation was shown between BMI and SGOT levels (B = 0.816), and BMI showed significance for predicting SGOT levels (t(53) = 2.141, p = 0.03). This means that for AP2 patients with the same weight and CRP level, higher SGOT levels can be expected as BMI increases.

4. Discussion

Schizophrenia and other severe psychiatric disorders show reciprocal association with metabolic disturbances [29,30]; obesity, DM, and metabolic syndrome are common comorbidities in patients with schizophrenia, especially those receiving AP treatment [7,31]. APs are strongly associated with the core components of metabolic syndrome, namely WG, glucose intolerance, and dyslipidemia [7,32]. More advanced adverse metabolic events are related to the induction of liver injury [33]. In this study, we showed that the SGAPs known
to induce more significant metabolic complications [1], referred to here as the AP2 group, are related to the severity of impairment of renal and hepatic function.

Recently, Druschky and his colleagues (2020) [34], assessing in a cross-sectional study the liver injury provoked by the use of APs, concluded that olanzapine, perazine, and clozapine were responsible for the most severe drug-induced liver damage. Similarly, we observed a positive association of elevated hepatic biochemical markers with the ongoing use of AP2 drugs, including paliperidone, olanzapine, asenapine, and clozapine. Conversely, the AP1 drugs, namely aripiprazole, amisulpride, quetiapine, risperidone, and ziprasidone, did not induce significant alterations in the liver function indices.

Generally, the antipsychotic drugs, together with neurologic, are referred to as the second most hepatotoxic drugs, after anti-infectious drugs [35]. To explain this sideeffect, several factors have been identified as important, because they affect the blood concentration of the drug, and therefore, it becomes toxic for the liver. Particularly, the pharmacokinetics of the drug and the first pass metabolism; the protein binding; the metabolic routes of the drug, and the body fluid status. In a study by Cho and colleagues [36], WG, rather than weight variability, was reported to induce liver dysfunction and non-alcoholic fatty liver disease (NAFLD) [36]. Of the SGAPs, the AP2, in contrast to the AP1 drugs, provoke rapid increase of body weight which is generally considered as the main inducer of [37]. The AP2 drugs induce metabolic complications, including hyper-triglyceridemia, hypercholesterolemia, and an increase in serum low density lipoprotein (LDL), even in the absence of WG [38,39]. There are also indications that subjects with dyslipidemia have a higher likelihood of developing liver disease than subjects without dyslipidemia [40].

Kidney dysfunction, also, is associated with dyslipidemia, specifically elevated levels of triglycerides, low levels of high-density cholesterol (HDL) and increased levels of small dense LDL, along with an increased CVD risk [41]. Long-term SGAP use has been linked with increased risk of chronic kidney dysfunction, regardless the age of the subjects using these drugs [12]. Additionally, use of SGAPs, and especially olanzapine, quetiapine, zotepine or risperidone, has been proposed as an exacerbator for the risk of CKD, especially in the presence of other comorbidities such as dyslipidemia, obesity, and DM [11]. Specifically, clozapine and quetiapine have been linked with interstitial nephritis and AKI [27,28]. In line, the forensic psychiatric patients in our case series were overweight, and those receiving AP2 were found to be at higher risk for major change in kidney markers.

It is of note that the increase in the level of uric acid in the AP2 patients was correlated with an increase in the CRP level, and with WG. Metabolic syndrome components, including WG, have been previously associated with high levels of CRP and uric acid [42], while CRP is highly predictive of subsequent risk of cardiovascular events and DM in apparently healthy men and women [43]. The correlation in our study of uric acid and CRP with administration of AP2 drugs supports our previous suggestion that this group of SGAPs is responsible for extensive metabolic and inflammatory complications [1,42,44].

Maintenance treatment for chronic illnesses, such as psychiatric diseases, is often long-term or lifelong, making drug selection a difficult process, due to the risk of extensive side effects in the function of various organs. We present here evidence that the use of SGAPs, and specifically of AP2s, can have adverse effects on liver and kidney function. Multiple regression analysis was performed to explore the contribution of weight, BMI, and level of CRP.

Our prospective study on the long-term side effects of SGAPs in a group of mentally disordered offenders offers significant distinguished information relevant to the specific type of AP, as these were categorized by the risk of weight gain and metabolic complications they provoke. As the patients were hospitalized, they were all following the same diet plan, and as such, the effect of diet on the specific markers was limited. Nevertheless, the study has some limitations. Due to the small study sample size, this analysis was conducted for the whole of the study period and not for the individual time points. In order to draw more robust conclusions on the hepatotoxic and nephrotoxic effect of the AP2 group of SGAPs, further investigation is needed with larger samples. Special consideration should
be given to populations such as forensic psychiatric patients, where other risk factors may amplify complications, for instance, multi-drug treatment, drug abuse, obesity, metabolic syndrome, and DM. Moreover, although the specific doses of SGAPs were recorded during our data collection, as well as the doses of the other drugs, these were not taken into account in the current investigation. Similarly, the specific effect on the liver or kidney function of the individual SGAP used in the study could not be established due to the small sample size. Another limitation of this study which evolved due to the small number of participants is that the regression analysis was run on a sample of 54 values which were not independent, and this is a limitation for drawing safe conclusions. The results of the study, however, indicate possible adverse effects on the kidney and liver of long-term administration of the AP2 group SGAPs, a finding which warrants further study in patients using this group of drugs.

5. Conclusions

Our study shows that the long-term use of SGAPs linked with the induction of weight gain, are more capable to provoke liver and kidney dysfunction, both relevant to the metabolic and inflammatory complications induced by them. Further investigation in higher study samples are needed to confirm and expand our results for proper treatment and prevention of these complications.

Author Contributions: Conceptualization: E.V.; Methodology: E.V., D.E., E.P., M.M. and E.-M.S.; Investigation: E.V., D.E. and E.P.; Data analysis: E.P., E.V. and D.E.; Writing-original draft preparation: E.V. and E.P.; Writing-review and editing: all. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according the guidelines of the Declaration of Helsinki, and approved by the scientific committee of the hospital (code number: Δ3B/34800/21/07/2020) and the research Ethics Committee of the Aristotle University of Thessaloniki (code number"4/26.01.2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data are available upon request to the correspondent authors.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Vassilopoulou, E.; Ethymiou, D.; Papatriantafyllou, E.; Markopoulou, M.; Sakellariou, E.-M.; Popescu, A.C. Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders. J. Pers. Med. 2021, 11, 1189. [CrossRef] [PubMed]

2. Marston, L.; Nazareth, I.; Petersen, I.; Walters, K.; Osborn, D.P.J. Prescribing of antipsychotics in UK primary care: A cohort study. BMJ Open 2014, 4, e006135. [CrossRef]

3. Correll, C.U.; Detraux, J.; De Lepeleire, J.; De Hert, M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015, 14, 119–136. [CrossRef] [PubMed]

4. Correll, C.U.; Lencz, T.; Malhotra, A.K. Antipsychotic drugs and obesity. Trends Mol. Med. 2011, 17, 97–107. [CrossRef] [PubMed]

5. Musil, R.; Obermeier, M.; Russ, P.; Hamerle, M. Weight gain and antipsychotics: A drug safety review. Expert Opin. Drug Saf. 2014, 14, 73–96. [CrossRef]

6. Salvi, V.; Barone-Adesi, F.; D’Ambrosio, V.; Albert, U.; Maina, G. High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder. Psychopharmacology 2015, 233, 49–56. [CrossRef]

7. De Hert, M.; Detraux, J.; Van Winkel, R.; Yu, W.; Correll, C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2011, 8, 114–126. [CrossRef]

8. Hwang, Y.J.; Dixon, S.N.; Reiss, J.P.; Wald, R.; Parikh, C.R.; Gandhi, S.; Shariff, S.Z.; Pannu, N.; Nash, D.M.; Rehman, F.; et al. Atypical Antipsychotic Drugs and the Risk for Acute Kidney Injury and Other Adverse Outcomes in Older Adults: A Population-Based Cohort Study: A Population-Based Cohort Study. Ann. Intern. Med. 2014, 161, 242–248. [CrossRef]

9. Jiang, Y.; McCombs, J.S.; Park, S.H. A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics. CNS Drugs 2017, 31, 319–326. [CrossRef]
Diseases 2020, 10, 48

10. Tzeng, N.-S.; Hsu, Y.-H.; Ho, S.-Y.; Kuo, Y.-C.; Lee, H.-C.; Shinn-Ying, H.; Chen, H.-A.; Chen, W.-L.; Chu, W.C.-C.; Huang, H.-L. Is schizophrenia associated with an increased risk of chronic kidney disease? A nationwide matched-cohort study. BMJ Open 2015, 5, e006777. [CrossRef]

11. Wang, H.-Y.; Huang, C.L.-C.; Feng, I.J.; Tsuang, H.-C. Second-generation antipsychotic medications and risk of chronic kidney disease in schizophrenia: Population-based nested case–control study. BMJ Open 2016, 8, e019868. [CrossRef] [PubMed]

12. Højlund, M.; Lund, L.C.; Herping, J.L.E.; Hastrup, M.B.; Damkier, P.; Henriksen, D.P. Second-generation antipsychotics and the risk of chronic kidney disease: A population-based case–control study. BMJ Open 2020, 10, e038247. [CrossRef] [PubMed]

13. Lv, Q.; Yi, Z. Antipsychotic Drugs and Liver Injury. Shanghai Arch. Psychiatry 2018, 30, 47–51. [CrossRef] [PubMed]

14. Manna, S.; Mitra, S. Complement Factor H and Related Proteins as Markers of Cardiovascular Risk in Pediatric Chronic Kidney Disease. Biomedicines 2022, 10, 1396. [CrossRef] [PubMed]

15. Mishra, J.; Dent, C.; Tarabishi, R.; Mitsnèfes, M.M.; Ma, Q.; Kelly, C.; Ruff, S.M.; Zahedi, K.; Shao, M.; Bean, J.; et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365, 1231–1238. [CrossRef]

16. Parikh, C.; Mishra, J.; Thiessen-Philbrook, H.; Dursun, B.; Ma, Q.; Kelly, C.; Dent, C.; Devarajan, P.; Edelstein, C. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006, 70, 199–203. [CrossRef] [PubMed]

17. Hosohata, K.; Ando, H.; Fujimura, A. Urinary Vanin-1 As a Novel Biomarker for Early Detection of Drug-Induced Acute Kidney Injury. J. Pharmacol. Exp. Ther. 2012, 341, 656–662. [CrossRef]

18. Malhotra, R.; Katz, R.; Jotwani, V.; Ambrosius, W.T.; Raphael, K.L.; Haley, W.; Rastogi, A.; Cheung, A.K.; Freedman, B.I.; Punzi, H.; et al. Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD. Clin. J. Am. Soc. Nephrol. 2020, 15, 349–358. [CrossRef] [PubMed]

19. Shrivastava, A.; Johnston, M.E. Weight-Gain in Psychiatric Treatment: Risks, Implications, and Strategies for Prevention and Management. Mens Sana Monogr. 2010, 8, 53–68. [CrossRef] [PubMed]

20. Chalasani, N.; Fontana, R.J.; Bonkovsky, H.L.; Watkins, P.B.; Davern, T.; Serrano, J.; Yang, H.; Rochon, J.; Drug Induced Liver Injury Network (DILIN). Causes, Clinical Features, and Outcomes from a Prospective Study of Drug-Induced Liver Injury in the United States. Gastroenterology 2008, 135, 1924–1934.e4. [CrossRef]

21. Aithal, G.P.; Watkins, P.B.; Andrade, R.J.; Larrey, D.; Molokhia, M.; Takikawa, H.; Hunt, C.M.; Wilke, R.A.; Avigan, M.; Kaplowitz, N.; et al. Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. Clin. Pharmacol. Ther. 2011, 89, 806–815. [CrossRef] [PubMed]

22. Dumortier, G.; Cabaret, W.; Stamatiadis, L.; Saba, G.; Benadhira, R.; Aubriot-Delmas, B.; Glikman, J.; Januel, D. Hepatic tolerance of atypical antipsychotic drugs. Encephale 2002, 28 Pt 1, 542–551. [CrossRef] [PubMed]

23. Licata, A.; Minissale, M.G.; Calvaruso, V.; Craxi, A. A focus on epidemiology of drug-induced liver injury: Analysis of a prospective cohort. Eur. Rev. Med Pharmacol. Sci. 2017, 21 (Suppl. S1), 112–121. [PubMed]

24. Vukotić, N.T.; Dordević, J.; Pejić, S.; Dordević, N.; Pajić, S.B. Antidepressants- and antipsychotics-induced hepatotoxicity. Arch. Toxicol. 2021, 95, 767–789. [CrossRef] [PubMed]

25. Telles-Correia, D.; Barbosa, A.; Cortez-Pinto, H.; Campos, C.; Rocha, N.B.F.; Machado, S. Psychotropic drugs and liver disease: A critical review of pharmacoepidemiology and liver toxicity. World J. Gastrointest. Pharmacol. Ther. 2017, 8, 26–38. [CrossRef]

26. Chou, A.I.W.; Lu, M.L.; Shen, W.W. Hepatotoxicity induced by clozapine: A case report and review of literature. Neuropsychiatr. Dis. Treat. 2014, 10, 1585–1587. [CrossRef] [PubMed]

27. McLaughlin, C.; Cooney, C.; Mullaney, R. Clozapine-induced interstitial nephritis in a patient with schizoaffective disorder in the forensic setting: A case report and review of the literature. Ir. J. Psychol. Med. 2019, 39, 106–111. [CrossRef]

28. He, L.; Peng, Y.; Fu, X.; Chen, X.; Liu, H. Dibenzoazepine Derivative Quetiapine- and Olanzapine-Induced Chronic Interstitial Nephritis. Ren. Fail. 2013, 35, 657–659. [CrossRef]

29. Kaidanovich-Beilin, O.; Cha, D.S.; McIntyre, R.S. Crossstalk between metabolic and neuropsychiatric disorders. F1000 Biol. Rep. 2012, 4, 14. [CrossRef]

30. Harris, L.W.; Guest, P.C.; Wayland, M.T.; Umrania, Y.; Krishnamurthy, D.; Rahmoune, H.; Bahn, S. Schizophrenia: Metabolic aspects of aetiology, biomarker of acute and future treatment strategies. Psychiatr. Neurosci. 2013, 38, 752–766. [CrossRef] [PubMed]

31. Dickerson, F.B.; Brown, C.H.; Kreyenbuhl, J.A.; Fang, L.; Goldberg, R.W.; Wohleiter, K.; Dixon, L.B. Obesity among individuals with serious mental illness. Acta Psychiatr. Scand. 2005, 113, 306–313. [CrossRef] [PubMed]

32. Vancampfort, D.; Stubbs, B.; Mitchell, A.J.; De Hert, M.; Wampers, M.; Ward, P.B.; Rosenbaum, S.; Correll, C.U. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: A systematic review and meta-analysis. World Psychiatry 2015, 14, 339–347. [CrossRef] [PubMed]

33. Lv, Q.; Yi, Z. Antipsychotic Drugs and Liver Injury. Shanghai Arch. Psychiatry 2018, 30, 47–51. [CrossRef] [PubMed]

34. Druschky, K.; Toto, S.; Bleich, S.; Baumgärtner, J.; Engel, R.R.; Grohmann, R.; Maier, H.B.; Neyazi, A.; Rudolph, Y.J.; Rüther, E.; et al. Severe drug-induced liver injury in patients under treatment with antipsychotic drugs: Data from the AMSP study. World J. Biol. Psychiatry 2020, 22, 373–386. [CrossRef] [PubMed]

35. Biour, M.; Ben Salem, C.; Chazouillères, O.; Grangé, J.-D.; Serfati, L.; Poupon, R. Hépatotoxicité des médicaments 14e mise à jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables. Gastroenterol. Clin. Biol. 2004, 28, 720–759. [CrossRef]
36. Cho, E.J.; Yu, S.J.; Jung, G.C.; Kwak, M.-S.; Yang, J.I.; Yim, J.Y.; Chung, G.E. Body weight gain rather than body weight variability is associated with increased risk of nonalcoholic fatty liver disease. Sci. Rep. 2021, 11, 14428. [CrossRef]
37. De Hert, M.; Schreurs, V.; Vancampfort, D.; Van Winkel, R. Metabolic syndrome in people with schizophrenia: A review. World Psychiatry 2009, 8, 15–22. [CrossRef]
38. Atmaca, M.; Kuloglu, M.; Tezcan, E.; Ustundag, B. Serum Leptin and Triglyceride Levels in Patients on Treatment With Atypical Antipsychotics. J. Clin. Psychiatry 2003, 64, 598–604. [CrossRef]
39. Melkersson, K.I.; Hulting, A.-L.; Brismar, K.E. Elevated Levels of Insulin, Leptin, and Blood Lipids in Olanzapine-Treated Patients with Schizophrenia or Related Psychoses. J. Clin. Psychiatry 2000, 61, 742–749. [CrossRef]
40. Kathak, R.R.; Sumon, A.H.; Molla, N.H.; Hasan, M.; Miah, R.; Tuba, H.R.; Habib, A.; Ali, N. The association between elevated lipid profile and liver enzymes: A study on Bangladeshi adults. Sci. Rep. 2022, 12, 1711. [CrossRef]
41. Rosenstein, K.; Tannock, L.R. Dyslipidemia in Chronic Kidney Disease. [Updated 2022 Feb 10]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. MDText.com, Inc.: South Dartmouth, MA, USA, 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK305899/ (accessed on 20 June 2022).
42. Efthymiou, D.; Zekakos, D.X.; Papatriantafyllou, E.; Ziagkas, E.; Petrelis, A.N.; Vasilopoulou, E. Gait Alterations in the Prediction of Metabolic Syndrome in Patients with Schizophrenia: A Pilot Study with PODOSmart® Insoles. Front. Psychiatry 2022, 13, 756600. [CrossRef] [PubMed]
43. Sah, S.K.; Khatiwada, S.; Pandey, S.; Kc, R.; Das, B.K.L.; Baral, N.; Lamsal, M. Association of high-sensitivity C-reactive protein and uric acid with the metabolic syndrome components. SpringerPlus 2016, 5, 269. [CrossRef] [PubMed]
44. Vasilopoulou, E.; Efthymiou, D.; Tsironis, V.; Athanassisi, P.; Chatzioannidis, S.; Kesogliou, T.; Severin, A.V.; Bozikas, V.P. The benefits of the Mediterranean diet in first episode psychosis patients taking antipsychotics. Toxicol. Rep. 2022, 9, 120–125. [CrossRef] [PubMed]